Mesoblast (MESO) News Today $17.30 +0.63 (+3.78%) Closing price 04:00 PM EasternExtended Trading$17.39 +0.09 (+0.52%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Mesoblast Limited (NASDAQ:MESO) Short Interest UpdateMesoblast Limited (NASDAQ:MESO - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,800,000 shares, a growth of 34.3% from the December 15th total of 1,340,000 shares. Based on an average daily volume of 384,900 shares, the days-to-cover ratio is presently 4.7 days.January 16 at 9:16 PM | marketbeat.comFirst FDA-Approved Mesenchymal Stromal Cell Therapy Ushers in a New Era of Regenerative MedicineJanuary 16 at 3:06 PM | tmcnet.comMesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?Mesoblast (NASDAQ:MESO) Shares Gap Down - What's Next?January 16 at 9:51 AM | marketbeat.comMesoblast (NASDAQ:MESO) Trading Down 2.2% - Here's WhyMesoblast (NASDAQ:MESO) Shares Down 2.2% - Should You Sell?January 15 at 12:49 PM | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down - Here's What HappenedMesoblast (NASDAQ:MESO) Shares Gap Down - Here's WhyJanuary 14 at 11:52 AM | marketbeat.comStocks making the biggest moves at noon: Telix, Mesoblast, Uranium and moreJanuary 13, 2025 | msn.comHealth Check: Mesoblast shares sink despite $260m placementJanuary 13, 2025 | msn.comMesoblast (NASDAQ:MESO) Sees Strong Trading Volume - Should You Buy?Mesoblast (NASDAQ:MESO) Sees Unusually-High Trading Volume - Still a Buy?January 10, 2025 | marketbeat.comHotCopper users flock to make sense of darling Mesoblast's 'proposed financing'January 10, 2025 | msn.comWhy are Mesoblast shares in a trading halt?January 10, 2025 | msn.comMesoblast (NASDAQ:MESO) Trading Down 3.4% - Here's WhyMesoblast (NASDAQ:MESO) Trading Down 3.4% - What's Next?January 7, 2025 | marketbeat.comUp 77% in a month! What's going on with the Mesoblast share price?January 7, 2025 | fool.com.auJane Street Group LLC Has $695,000 Position in Mesoblast Limited (NASDAQ:MESO)Jane Street Group LLC raised its stake in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) by 46.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 85,102 shares of the company's stock after acquiring an additional 26,959 shares durinJanuary 4, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down - Here's WhyMesoblast (NASDAQ:MESO) Shares Gap Down - Here's WhyJanuary 3, 2025 | marketbeat.comWhy Appen, Brainchip, Liontown, and Mesoblast shares are falling todayJanuary 2, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?Mesoblast (NASDAQ:MESO) Shares Gap Up - Should You Buy?January 2, 2025 | marketbeat.comWhy Brainchip, Fortescue, Mesoblast, and QBE shares are racing higher todayJanuary 1, 2025 | msn.comMesoblast After Approval: Stock Is Buoyant Now, But Unpredictable OverallDecember 30, 2024 | seekingalpha.comMesoblast (NASDAQ:MESO) Reaches New 52-Week High - Time to Buy?Mesoblast (NASDAQ:MESO) Reaches New 1-Year High - What's Next?December 30, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Trading Down 5.7% - What's Next?Mesoblast (NASDAQ:MESO) Shares Down 5.7% - What's Next?December 27, 2024 | marketbeat.comWhy Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher todayDecember 26, 2024 | msn.comMesoblast (NASDAQ:MESO) Stock Price Up 6.1% - Still a Buy?Mesoblast (NASDAQ:MESO) Stock Price Up 6.1% - Time to Buy?December 26, 2024 | marketbeat.comJefferies Downgrades Mesoblast Limited - Depositary Receipt () (MESO)December 23, 2024 | msn.comMesoblast downgraded to Hold from Buy at JefferiesDecember 23, 2024 | markets.businessinsider.comMesoblast (NASDAQ:MESO) Downgraded by Jefferies Financial Group to HoldJefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a report on Monday.December 23, 2024 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Mesoblast (MESO)December 20, 2024 | markets.businessinsider.comMesoblast price target raised to $30 from $18 at MaximDecember 20, 2024 | markets.businessinsider.comMesoblast price target raised to $15 from $11 at Piper SandlerDecember 20, 2024 | markets.businessinsider.comWhy the Mesoblast share price is diving 18% after an FDA winDecember 20, 2024 | msn.comPiper Sandler Increases Mesoblast (NASDAQ:MESO) Price Target to $15.00Piper Sandler raised their price objective on Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a report on Thursday.December 19, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Sees Strong Trading Volume - What's Next?Mesoblast (NASDAQ:MESO) Sees Unusually-High Trading Volume - Here's What HappenedDecember 19, 2024 | marketbeat.comMesoblast Target of Unusually High Options Trading (NASDAQ:MESO)Mesoblast Limited (NASDAQ:MESO - Get Free Report) saw unusually large options trading activity on Thursday. Investors purchased 3,838 put options on the stock. This represents an increase of 350% compared to the average daily volume of 852 put options.December 19, 2024 | marketbeat.comMesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock SurgesDecember 19, 2024 | benzinga.comMesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyDecember 18, 2024 | globenewswire.comUS FDA approves Mesoblast's cell therapy for graft-versus-host diseaseDecember 18, 2024 | reuters.comMesoblast to be Added to Nasdaq Biotechnology IndexDecember 18, 2024 | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Up - Should You Buy?Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?December 17, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Hits New 52-Week High - Time to Buy?Mesoblast (NASDAQ:MESO) Hits New 12-Month High - Should You Buy?December 16, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Stock Price Up 13.6% - Still a Buy?Mesoblast (NASDAQ:MESO) Shares Up 13.6% - Still a Buy?December 13, 2024 | marketbeat.com3 ASX Growth Companies With Insider Ownership Up To 38%December 9, 2024 | finance.yahoo.comMesoblast’s Revascor Gains FDA Designation BoostDecember 9, 2024 | markets.businessinsider.comFDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseDecember 4, 2024 | globenewswire.comRevascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationDecember 2, 2024 | globenewswire.comTop ASX shares to buy in December 2024November 30, 2024 | msn.comMesoblast Ltd. ADRNovember 27, 2024 | wsj.comMesoblast Announces Director Change and ShareholdingsNovember 18, 2024 | markets.businessinsider.comMesoblast Limited’s AGM Resolutions Gain Strong ApprovalNovember 16, 2024 | markets.businessinsider.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?November 15, 2024 | marketbeat.comMesoblast Limited Advances in Drug Development and CommercializationNovember 15, 2024 | markets.businessinsider.comMesoblast Limited Outlines Future Strategies and Growth ProspectsNovember 15, 2024 | markets.businessinsider.com Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address MESO Media Mentions By Week MESO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MESO News Sentiment▼0.710.72▲Average Medical News Sentiment MESO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MESO Articles This Week▼94▲MESO Articles Average Week Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News Today RVMD News Today LNTH News Today BPMC News Today BBIO News Today LEGN News Today ELAN News Today CYTK News Today NUVL News Today GRFS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MESO) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
